$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Announces

New Post Public Reply Private Reply Replies (0) Message Board
Lee Adams Lee Adams #23
274
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

Formulation based on prior patents by NRx founder

Achieved pH neutral formulation of ketamine, potentially enabling both intravenous (IV) and subcutaneous (SQ) administration

Company expects Composition of Matter patent protection

Company previously executed joint development agreement with US manufacturer of insulin pumps

RADNOR, Pa., April 15, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx", the "Company" , a clinical-stage biopharmaceutical company, today announced that the Company has developed a novel, proprietary formulation of IV Ketamine for use as HTX-100. This new formulation has the key advantage of achieving neutral pH, in contrast to the acidic pH of generic formulations of ketamine. Acidic substances are tolerated when diluted for intravenous use, but cause pain and may cause skin ulcers if administered subcutaneously. This patentable invention may enable the administration of ketamine in insulin pump-like devices in the clinic setting, eliminating the requirement for intravenous infusion personnel. NeuroRx, Inc. previously executed a joint development agreement with a manufacturer of insulin pumps but has been awaiting a suitable, pH neutral formulation of ketamine.

With this proprietary formulation, developed with our partner Nephron Pharmaceuticals, a leading sterile products manufacturer, NRx is expected to generate one or more patents, such as composition of matter or formulation.

HTX-100 is expected to be marketed by HOPE Therapeutics, Inc., a wholly owned subsidiary of NRx.

"The current formulation of IV Ketamine was developed for battlefield use in the 1960s and has remained relatively static since then. With our new formulation, and Nephron's state of the art manufacturing expertise, we are pleased to be approaching the market with an improved formulation ready for use in modern medicine," said Dr. Jonathan Javitt, Founder, Chairman and Chief Scientist of NRx Pharmaceuticals. "Development of a pH-neutral, subcutaneous form of ketamine administration enables a significantly less complex route of administration in the outpatient setting. Moreover, advances in insulin pump technology create the potential to monitor the brain wave activity and other physiologic parameters associated with ketamine administration and modulate ketamine therapy based on the patient's individual physiologic response."

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (http://www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRx Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.


https://c212.net/c/img/favicon.png?sn=CL87341...2024-04-15 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-announces-development-of-new-proprietary-formulation-of-htx-100-iv-ketamine-302116345.html

SOURCE NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals Inc. (NRXP) Stock Research Links

NRXP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 238

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 0

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 0

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading